Eli L. Thomssen

Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA.

Afmedica, Inc. develops medical and drug products. It develops perivascular technology using the drug rapamycin to treat peripheral vascular disease, coronary artery disease, and end stage renal disease. The company was founded in 2002 and is located in Kalamazoo, MI.

Azenic, Inc. manufactured and marketed dental devices. Its product DHP, was commercially launched to advance infection prevention and prevent cross-contamination in the dental office while offering an excellent stand-in product for use in difficult dental applications such as crown and bridge work, certain surgical applications and as a guaranteed back-up for a dentists busy days. The company was founded in September 2005 and was headquartered in Kalamazoo, MI.

MedElute Inc. developed drug-eluting materials for treating post-surgical adhesions. Post-surgical adhesion formation is a natural consequence of surgery, resulting when tissue repairs itself following incision, cauterization, suturing, or other means of trauma. The company was founded in 2005 and is headquartered in Kalamazoo, MI.

Vestaron Corp. develops and markets bioinsecticides derived from naturally occurring peptides. It offers the following brands: Spear-T for the treatment of thrips, Spear-P controls Colorado Potato beetle, and Spear-C protects crops from lepidopteran pests. The company was founded by Glenn F. King in 2005 and is headquartered in Durham, NC.

Armune BioScience, Inc. researches and develops diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. The firm's technology is based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness. The company was founded by Eli L. Thomssen in 2008 and is headquartered in Kalamazoo, MI.

Apjohn Group LLC invests in pharamaceutical companies. It works with innovators to launch life science companies. The company is headquartered in Kalamazoo, MI.